ESR1 and breast neoplasm: However, recent studies revealed that breast tumors acquire mutations in the ER ligand-binding domains (L536 N, Y537S, Y537N, and D538G) that facilitate the constitutive activity of these mutant ER (MT-ER) in the absence of ligand [29–32].